Comments Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. 560 F.3d 1366 (Fed. Cir. 2009) and Wyeth v. Diana Levine 129 S.Ct 1187 (2009)

Case notes concerning Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. 560 F.3d 1366 (Fed. Cir. 2009) and Wyeth v. Diana Levine 129 S.Ct 1187 (2009) View in PDF.…

The Patent Prosecution Highway: Is Life in the ‘Fast Lane’ Worth the Cost?

by Alicia Pitts* and Joshua Kim, Ph.D. – Search queries may reveal quite sensitive information about the querier. Even though many queries are not directly associated with a particular person, it has been argued…

Of Babies and Bathwater – The Impact of In Re Bilski on Life Science Patents

by Michael J. Shuster, Ph.D., and Juleen Konkel – Tension between the broad language of 35 U.S.C. § 101 and limitations of its scope is an emerging issue in recent court decisions attempting…

A Better Carrot Incentivizing Patent Reexamination

by James W. Beard – Patent reexamination provides a potentially powerful alternative to full invalidity litigation, but it has been underutilized because of deficiencies in the patent reexamination system. The system’s appeal as…